Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01498458 | Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer(PazoX) | completed | Phase 1 | 9 | GBG Forschungs GmbHOTHER | 1 | Jun 10, 2022 | clinicaltrials |
| NCT03518242 | Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer | completed | Phase 1 | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 8, 2022 | clinicaltrials |
| NCT02379247 | BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | completed | Phase 1 / Phase 2 | 43 | Priyanka SharmaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT01033032 | Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 78 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT01134250 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | completed | Phase 1 / Phase 2 | 48 | Philogen S.p.A.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03366428 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer | completed | Phase 1 | 51 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Apr 12, 2022 | clinicaltrials |
| NCT01655225 | A Study of LY3023414 in Participants With Advanced Cancer | completed | Phase 1 | 156 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 8, 2022 | clinicaltrials |
| NCT00317603 | Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients | completed | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT00880464 | Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer | completed | Phase 1 | 8 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT02646748 | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | completed | Phase 1 | 159 | Incyte CorporationINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02111850 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2022 | clinicaltrials |
| NCT01724606 | Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) | completed | Phase 1 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT03524170 | Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | completed | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT00566618 | Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis | completed | Phase 1 / Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02562378 | T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer(THELMA) | completed | Phase 1 | 15 | MedSIROTHER | 2 | Feb 23, 2022 | clinicaltrials |
| NCT02178722 | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | completed | Phase 1 / Phase 2 | 444 | Incyte CorporationINDUSTRY | 1 | Feb 14, 2022 | clinicaltrials |
| NCT01391143 | Safety Study of MGA271 in Refractory Cancer | completed | Phase 1 | 179 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT01976169 | Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1) | completed | Phase 1 | 29 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00967577 | 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors | completed | Phase 1 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT02947165 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 9 | Jan 31, 2022 | clinicaltrials |
| NCT02586675 | TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT03281824 | Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients | completed | Phase 1 | 27 | Alteogen, Inc.INDUSTRY | 1 | Jan 18, 2022 | clinicaltrials |
| NCT00952692 | Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 12 | Michael Morse, MDOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT03166085 | PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer | completed | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02820961 | Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer | completed | Phase 1 | 61 | Syndax PharmaceuticalsINDUSTRY | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT01594398 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer(ENCORE110) | completed | Phase 1 | 14 | Syndax PharmaceuticalsINDUSTRY | 1 | Nov 19, 2021 | clinicaltrials |
| NCT01421017 | Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | completed | Phase 1 / Phase 2 | 31 | NYU Langone HealthOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT02914470 | Carboplatin-cyclophosphamide Combined With Atezolizumab(PROLOG) | completed | Phase 1 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT02018458 | Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer | completed | Phase 1 / Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT01802970 | Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients | completed | Phase 1 | 10 | Baylor Research InstituteOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT00096356 | Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer(CoQ10) | completed | Phase 1 | 236 | Wake Forest University Health SciencesOTHER | 1 | Sep 29, 2021 | clinicaltrials |
| NCT02001974 | Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) | completed | Phase 1 | 33 | Dompé Farmaceutici S.p.AINDUSTRY | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04103853 | Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer | completed | Phase 1 | 63 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Sep 24, 2021 | clinicaltrials |
| NCT03135171 | Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab | completed | Phase 1 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 10, 2021 | clinicaltrials |
| NCT01674842 | Cisplatin + RT for Triple Negative Breast Cancer | completed | Phase 1 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02780713 | A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects(PK) | completed | Phase 1 | 14 | AstraZenecaINDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | completed | Phase 1 / Phase 2 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02227082 | Olaparib and Radiotherapy in Inoperable Breast Cancer | completed | Phase 1 | 7 | The Netherlands Cancer InstituteOTHER | 1 | Aug 4, 2021 | clinicaltrials |
| NCT02167854 | Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer | completed | Phase 1 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03092934 | A Study of AK-01 (LY3295668) in Solid Tumors | completed | Phase 1 / Phase 2 | 13 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2021 | clinicaltrials |
| NCT01023477 | Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial) | completed | Phase 1 / Phase 2 | 12 | Inova Health Care ServicesOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04905667 | Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® | completed | Phase 1 | 87 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 27, 2021 | clinicaltrials |
| NCT03411161 | S 81694 Plus Paclitaxel in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 22 | Institut de Recherches Internationales ServierOTHER | 4 | May 25, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT02732119 | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.(TRINITI-1) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 10, 2022source: clinicaltrials